CN115252701A - Oral liquid for inactivating helicobacter pylori and production method thereof - Google Patents

Oral liquid for inactivating helicobacter pylori and production method thereof Download PDF

Info

Publication number
CN115252701A
CN115252701A CN202210206207.9A CN202210206207A CN115252701A CN 115252701 A CN115252701 A CN 115252701A CN 202210206207 A CN202210206207 A CN 202210206207A CN 115252701 A CN115252701 A CN 115252701A
Authority
CN
China
Prior art keywords
acid
oral liquid
helicobacter pylori
inactivating
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210206207.9A
Other languages
Chinese (zh)
Inventor
汪维武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Jieyoutang Biotechnology Co ltd
Original Assignee
Guangdong Jieyoutang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Jieyoutang Biotechnology Co ltd filed Critical Guangdong Jieyoutang Biotechnology Co ltd
Priority to CN202210206207.9A priority Critical patent/CN115252701A/en
Publication of CN115252701A publication Critical patent/CN115252701A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/86—Violaceae (Violet family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses an oral liquid for inactivating helicobacter pylori and a production method thereof, wherein the oral liquid comprises the following components: the Chinese herbal medicine compound extract accounts for 3-4% of the total weight; biological compound acid accounting for 0.1-0.2% of the total weight; salt accounting for 0.5 to 0.9 percent of the total weight; purified water, accounting for more than 95% of the total weight, comprising: s1, diluting an unsaturated solution of Chinese herbal medicine extract and biological composite acid by using purified water; s2, adding 0.5-0.9% of table salt, and placing the mixture in an ion exchange tank: s3, performing ion exchange treatment by adopting cationic resin and chelating resin; and S4, filtering to obtain the finished product of oral liquid. The invention has the advantages of wide raw materials, low production cost and no pollution in the production process, and after the obtained product passes the pilot test, all experimenters pass the detection of C13 or C14 and all the experimenters turn positive into negative. Is a safe product really meeting the health requirements of the masses of people.

Description

Oral liquid for inactivating helicobacter pylori and production method thereof
Technical Field
The invention relates to the technical field of biological medicines, in particular to an oral liquid for inactivating helicobacter pylori and a production method thereof.
Background
According to the list of carcinogens published by the world health organization international agency for research on cancer, helicobacter pylori (infection) is among a class of carcinogens. The WHO statistical data show that more than 50% of people worldwide have been infected by helicobacter pylori, the bacterial infection firstly causes chronic gastritis and gastric ulcer and gastric atrophy, and severe people develop gastric cancer. Prevention and control of gastric cancer has been attracting increasing attention.
Studies have shown that helicobacter pylori lives in the pylorus region of the human stomach and is one of the most common bacterial pathogens. Helicobacter pylori parasitizes in gastric mucosal tissues, 67 to 80 percent of gastric ulcers and 95 percent of duodenal ulcers are caused by helicobacter pylori, and helicobacter pylori infection is parallel to the death rate of gastric cancer. Therefore, the helicobacter pylori infection can be found as soon as possible, the helicobacter pylori can be killed timely and effectively, and the method has great significance for preventing and controlling gastric cancer.
Therefore, we propose a method for producing an oral liquid for inactivating helicobacter pylori to solve the above problems.
Disclosure of Invention
The invention aims to solve the problems that a product for inactivating helicobacter pylori is difficult to take, difficult to transport, high in production cost, complex in steps and not suitable for large-scale production in the prior art, and provides the oral liquid for inactivating the helicobacter pylori and the production method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
an oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine composite extract accounts for 3-4% of the total weight;
biological compound acid accounting for 0.1-0.2% of the total weight;
salt accounting for 0.5-0.9% of the total weight;
purified water accounting for more than 95 percent of the total weight.
Preferably, the Chinese herbal medicine compound extract comprises:
Figure BSA0000267680810000021
preferably, the biocomposite acid comprises:
0.03-0.05% malic acid
0.01-0.03% citric acid
0.01-0.05% of salicylic acid
0.005-0.02% hypochlorous acid
0.05-0.09% amino acid.
A method for producing an oral liquid for inactivating helicobacter pylori, comprising:
s1, diluting an unsaturated solution of Chinese herbal medicine extract and biological composite acid by using purified water;
s2, adding 0.5-0.9% of salt, and placing in an ion exchange tank:
s3, performing ion exchange treatment by adopting cationic resin and chelating resin;
and S4, filtering to obtain the finished product of the oral liquid.
Preferably, the preparation of the Chinese herbal medicine extract comprises the following steps:
s1, mixing purslane, dandelion, chinese violet, chrysanthemum morifolium, honeysuckle, sweet wormwood, common andrographis herb and houttuynia cordata, and soaking in alcohol liquid;
s2, obtaining a purified mixture by an extraction method;
and S3, diluting the mixture with purified water to obtain the compound Chinese herbal medicine liquid.
Preferably, the preparation of the biocomposite acid:
s1, mixing malic acid, citric acid, salicylic acid, citric acid and hypochlorous acid;
and S2, adding purified water to prepare and mix the unsaturated solution of the composite acid.
Preferably, the dosage of each Chinese herbal medicine accounts for the total weight of the Chinese herbal medicines in percentage by weight:
Figure BSA0000267680810000031
preferably, the proportion of biocomposite acids is as follows:
0.03-0.05% malic acid;
0.01-0.03% citric acid;
0.01-0.05% salicylic acid;
0.005-0.02% hypochlorous acid;
0.05-0.09% amino acid.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention has wide raw materials and low production cost, no pollution is caused in the production process, and after the obtained product passes the pilot test, all experimenters pass the detection of C13 or C14 and all the experimenters are converted into negative. Is a safe product really meeting the health requirements of the masses of people;
2. the compound Chinese herbal medicine extract contains proper chlorogenic acid, isochlorogenic acid, arteannuin A, B, arteannuin, sunflower aldehyde, capric acid, anthraquinone glycoside, full grass glycoside and the like, and has strong inactivation and inhibition effects on staphylococcus aureus, staphylococcus albus, gram bacteria, pseudomonas aeruginosa, escherichia coli, acid-fast bacillus, spore bacteria, helicobacter pylori, viruses and other harmful microorganisms. In the proportion of the compound acid, the compound acid contains a proper amount of micromolecular hypochlorous acid, can quickly penetrate through cell walls of harmful microorganisms, replace human leukocytes to kill cell nuclei, can also promote the regeneration function of epithelial cell tissues, accelerate healing of ulcer and injury, enhance the immune function of a human body, can effectively prevent and control gastric cancer and intestinal cancer, and further guarantee the health of people.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments.
Example one
An oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine composite extract accounts for 3 percent of the total weight;
biological composite acid accounting for 0.1 percent of the total weight;
salt accounting for 0.5 percent of the total weight;
purified water, 96.4% of the total weight.
Example two
An oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine composite extract accounts for 4 percent of the total weight;
biological composite acid accounting for 0.2 percent of the total weight;
salt accounting for 0.8 percent of the total weight;
purified water accounting for more than 95 percent of the total weight.
EXAMPLE III
An oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine composite extract accounts for 4 percent of the total weight;
biological composite acid accounting for 0.15 percent of the total weight;
salt accounting for 0.7 percent of the total weight;
purified water, 95.15% of the total weight.
Example four
The Chinese herbal medicine compound extract comprises:
Figure BSA0000267680810000051
Figure BSA0000267680810000061
example four
Figure BSA0000267680810000062
EXAMPLE five
Figure BSA0000267680810000063
Figure BSA0000267680810000071
An oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine compound extract accounts for 3-4% of the total weight;
biological composite acid accounting for 0.1-0.2% of the total weight;
salt accounting for 0.5 to 0.9 percent of the total weight;
purified water accounting for more than 95 percent of the total weight.
Preferably, the Chinese herbal medicine compound extract comprises:
Figure BSA0000267680810000072
preferably, the biocomposite acid comprises:
0.03-0.05% malic acid
0.01-0.03% citric acid
0.01-0.05% of salicylic acid
0.005-0.02% hypochlorous acid
0.05-0.09% amino acid.
The invention relates to a production method of an oral liquid for inactivating helicobacter pylori, which comprises the steps of selecting several groups of Chinese herbal medicine extracts, biological compound acid and the like to be combined into the oral liquid according to the principle of homology of medicine and food; wherein, the total weight of the Chinese herbal medicine compound extract is 3-4%, the biological compound acid accounts for 0.1-0.2%, the salt accounts for 0.5-0.9%, and more than 95% of purified water.
The Chinese herbal medicine extract is prepared by mixing various Chinese herbal medicines, soaking in alcohol liquid, extracting to obtain a purified mixture, and diluting with purified water to obtain a composite Chinese herbal medicine liquid.
The dosage of the Chinese herbal medicines accounts for the total weight of the Chinese herbal medicines in percentage by weight:
Figure BSA0000267680810000081
the preparation method of the biological composite acid comprises the following steps:
malic acid, citric acid, salicylic acid, citric acid, hypochlorous acid and the like are mixed according to the following mixture ratio, and purified water is added to mix and mix to obtain a composite acid unsaturated solution. The proportions are as follows:
0.03-0.05% malic acid
0.01-0.03% citric acid
0.01-0.05% of salicylic acid
0.005-0.02% hypochlorous acid
0.05-0.09% amino acid
Finally, diluting the Chinese herbal medicine extract and the composite acid unsaturated solution with purified water, adding 0.5-0.9% of salt, and placing in an ion exchange tank. Then, the cation resin and the chelating resin are used for ion exchange treatment, and after filtration, the finally obtained liquid is the product of the invention.
The invention has wide raw materials and low production cost, no pollution is caused in the production process, and after the obtained product passes the pilot test, all experimenters pass the detection of C13 or C14 and all the experimenters are converted into negative. Is a safe product really meeting the health requirements of the masses of people.
The composite Chinese herbal medicine extract contains a proper amount of chlorogenic acid, isochlorogenic acid, arteannuin A, B, arteannuin, decanal, decanoic acid, anthraquinone glycoside, full grass glycoside-containing and the like, and has strong inactivation and inhibition effects on staphylococcus aureus, staphylococcus albus, gram bacteria, pseudomonas aeruginosa, escherichia coli, acid-fast bacillus, spore bacteria, helicobacter pylori, viruses and other harmful microorganisms. In the proportion of the compound acid, the compound acid contains a proper amount of micromolecular hypochlorous acid which can rapidly penetrate through cell walls of harmful microorganisms to replace human leucocytes to kill cell nuclei, can also promote the regeneration function of epithelial cell tissues, accelerate the healing of ulcer and injury, enhance the immunologic function of human bodies, can effectively prevent and control gastric cancer and intestinal cancer, and further ensure the health of people.
The invention aims to provide a production method of an oral liquid for inactivating helicobacter pylori, which is produced for effectively preventing and controlling gastric cancer and ensuring human health. The method has been successful in safety performance, stability performance, toxicological experiment and inactivation effect of the product after a plurality of experiments. And experimental data obtained in the pilot plant test process of the product show that the invention conforms to the principle of homology of medicine and food, has simple production process and is suitable for large-scale production.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.

Claims (8)

1. An oral liquid for inactivating helicobacter pylori, comprising:
the Chinese herbal medicine composite extract accounts for 3-4% of the total weight;
biological composite acid accounting for 0.1-0.2% of the total weight;
salt accounting for 0.5-0.9% of the total weight;
purified water accounting for more than 95 percent of the total weight.
2. The oral liquid for inactivating helicobacter pylori according to claim 1, wherein the Chinese herbal medicine compound extract comprises:
Figure FSA0000267680800000011
3. the method for producing an oral liquid for inactivating helicobacter pylori according to claim 2, wherein the biocomposite acid comprises:
0.03-0.05% malic acid
0.01-0.03% citric acid
0.01-0.05% of salicylic acid
0.005-0.02% hypochlorous acid
0.05-0.09% amino acid.
4. A method for producing an oral liquid for inactivating helicobacter pylori, which comprises the following steps:
s1, diluting an unsaturated solution of Chinese herbal medicine extract and biological composite acid by using purified water;
s2, adding 0.5-0.9% of salt, and placing in an ion exchange tank:
s3, performing ion exchange treatment by adopting cationic resin and chelating resin;
and S4, filtering to obtain the finished product of the oral liquid.
5. The method for producing an oral liquid for inactivating helicobacter pylori according to claim 4, wherein the preparation of the herbal extract comprises:
s1, mixing purslane, dandelion, chinese violet, chrysanthemum morifolium, honeysuckle, sweet wormwood, common andrographis herb and houttuynia cordata, and soaking in alcohol liquid;
s2, obtaining a purified mixture by an extraction method;
and S3, diluting the mixture with purified water to obtain the compound Chinese herbal medicine liquid.
6. The method for producing an oral liquid for inactivating helicobacter pylori according to claim 4, wherein the preparation of the biocomposite acid comprises:
s1, mixing malic acid, citric acid, salicylic acid, citric acid and hypochlorous acid;
and S2, adding purified water to prepare and mix the unsaturated solution of the composite acid.
7. The method for producing an oral liquid for inactivating helicobacter pylori according to claim 5, wherein the dosage of each Chinese herbal medicine accounts for the following percentage of the total weight of the Chinese herbal medicines:
Figure FSA0000267680800000031
8. the method for producing an oral liquid for inactivating helicobacter pylori according to claim 6, wherein the ratio of the biocomposite acid is as follows:
0.03-0.05% malic acid;
0.01-0.03% citric acid;
0.01-0.05% salicylic acid;
0.005-0.02% hypochlorous acid;
0.05-0.09% amino acid.
CN202210206207.9A 2022-03-04 2022-03-04 Oral liquid for inactivating helicobacter pylori and production method thereof Pending CN115252701A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210206207.9A CN115252701A (en) 2022-03-04 2022-03-04 Oral liquid for inactivating helicobacter pylori and production method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210206207.9A CN115252701A (en) 2022-03-04 2022-03-04 Oral liquid for inactivating helicobacter pylori and production method thereof

Publications (1)

Publication Number Publication Date
CN115252701A true CN115252701A (en) 2022-11-01

Family

ID=83758265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210206207.9A Pending CN115252701A (en) 2022-03-04 2022-03-04 Oral liquid for inactivating helicobacter pylori and production method thereof

Country Status (1)

Country Link
CN (1) CN115252701A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101947236A (en) * 2010-03-11 2011-01-19 沙建民 Method for taking hypochloric acid
CN102274352A (en) * 2011-07-30 2011-12-14 胡海舰 Traditional Chinese medicine prescription for treating septicemia
CN108478500A (en) * 2018-03-13 2018-09-04 弘美制药（中国）有限公司 A kind of composition and its application for oral cavity
CN111150778A (en) * 2020-02-26 2020-05-15 广州市白云区天芳化妆品厂 A sterilizing disinfectant with high safety and high efficiency for oral mucosa, skin and general articles, and its preparation method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101947236A (en) * 2010-03-11 2011-01-19 沙建民 Method for taking hypochloric acid
CN102274352A (en) * 2011-07-30 2011-12-14 胡海舰 Traditional Chinese medicine prescription for treating septicemia
CN108478500A (en) * 2018-03-13 2018-09-04 弘美制药（中国）有限公司 A kind of composition and its application for oral cavity
CN111150778A (en) * 2020-02-26 2020-05-15 广州市白云区天芳化妆品厂 A sterilizing disinfectant with high safety and high efficiency for oral mucosa, skin and general articles, and its preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
史代萌: "四联疗法联合蒲地蓝消炎口服液对幽门螺杆菌的补救治疗" *

Similar Documents

Publication Publication Date Title
CN1951208B (en) Nutrient for animal and preparation process thereof
CN111265598A (en) Composite broad-spectrum antibacterial agent and preparation method thereof
CN101428047A (en) Process for producing pericarpium granati total phenols and uses thereof
Sundaramurthi et al. Effect of tulsi (Ocimum sanctum) as a disinfectant for water treatment
CN114145293A (en) Composite disinfectant containing natural plant extracts and preparation method thereof
CN110025691A (en) A kind of compound houttuynia cordata preparation and preparation method and application
CN113080206A (en) Aromatic essential oil air disinfectant and preparation method thereof
CN115252701A (en) Oral liquid for inactivating helicobacter pylori and production method thereof
CN104147076A (en) Lonicera japonica antibacterial agent for restraining micrococcus luteus
CN102225146A (en) Formula and production technology of traditional Chinese medicine injection for controlling bird flu
CN115531464B (en) Traditional Chinese medicine composition for resisting mycoplasma caprae pneumonia as well as preparation method and application thereof
CN106562110A (en) Chinese herbal medicinal feed additive composition for salvelinus malma and preparation method and use thereof
CN106890202A (en) Purslane extract solution and preparation method thereof
CN106942278B (en) Method for extracting antibacterial composition from limulus reagent production waste
CN110013506A (en) A kind of extracting method and application of the effective sterilization component of cordate houttuynia
CN110693736A (en) Pure natural plant essential oil sterilization hand sanitizer and preparation method thereof
CN103181597B (en) Ledum palustre detoxication health care liquid and preparation method thereof
CN102389570A (en) Antiseptic-free vaccine
CN109316533B (en) Fermented traditional Chinese medicine compound preparation for removing endotoxin in pig body and application thereof
CN113181275A (en) Fermented traditional Chinese medicine for preventing and treating bovine sarcoidosis and preparation method thereof
KR101982974B1 (en) Alkaline Ionized Composition And Antidiabetics Comprising The Same
CN104187658B (en) Columba livia health care oral liquid and application thereof
CN110507752B (en) Acne-removing traditional Chinese medicine composition, preparation method thereof and acne-removing ointment
DE60031532T2 (en) CONCENTRATES OF NATURAL DYES AND ANTIMICROBIAL NUTRIENTS OF PLANT ORIGIN
CN103356739B (en) A kind of Shuanghuanglian oral liquid for livestock and extracting method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221101

WD01 Invention patent application deemed withdrawn after publication